UnknownPhase 3NCT00651261
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
Studying Acute basophilic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Alliance for Clinical Trials in Oncology
- Principal Investigator
- Richard M. Stone, MDDana-Farber Cancer Institute
- Intervention
- cytarabine(drug)
- Enrollment
- 717 enrolled
- Eligibility
- 18-59 years · All sexes
- Timeline
- 2008
Study locations (30)
- UAB Comprehensive Cancer Center, Birmingham, Alabama, United States
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- University of California Davis Cancer Center, Sacramento, California, United States
- Aurora Presbyterian Hospital, Aurora, Colorado, United States
- Boulder Community Hospital, Boulder, Colorado, United States
- Penrose Cancer Center at Penrose Hospital, Colorado Springs, Colorado, United States
- St. Anthony Central Hospital, Denver, Colorado, United States
- Porter Adventist Hospital, Denver, Colorado, United States
- Presbyterian - St. Luke's Medical Center, Denver, Colorado, United States
- St. Joseph Hospital, Denver, Colorado, United States
- Rose Medical Center, Denver, Colorado, United States
- CCOP - Colorado Cancer Research Program, Denver, Colorado, United States
- Swedish Medical Center, Englewood, Colorado, United States
- North Colorado Medical Center, Greeley, Colorado, United States
- Sky Ridge Medical Center, Lone Tree, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI) · Novartis Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00651261 on ClinicalTrials.govOther trials for Acute basophilic leukemia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT01627041Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT00898456Multidrug Resistance Genes in Patients With Acute Myeloid LeukemiaAlliance for Clinical Trials in Oncology